Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bioucenta
- Development stage
- Preclinical
- Lead developer
- Formycon
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
BioUcenta is a biosimilar to Lucentis (ranibizumab), developed as a monoclonal antibody therapy for the treatment of diabetic macular edema (DME), wet (neovascular) age-related macular degeneration (AMD), and diabetic retinopathy. BioUcenta is specifically intended to increase access to advanced biologic ophthalmic therapy in Sub-Saharan Africa by providing a high-quality, affordable alternative. The drug inhibits vascular endothelial growth factor A (VEGF-A) in the retina, thereby blocking abnormal blood vessel growth and leakage—key processes in vision loss associated with these retinal diseases. Ranibizumab, the reference drug, has been widely used globally for these indications, but BioUcenta is being introduced to expand reach in previously underserved populations[1][2][3][4][6][7][8].
- Brand names
- BioUcenta
- Other names
- FYB201FYB-201FYB 201
02
Targets
Beyond the preview
Go deeper on bioucenta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bioucenta.